Canadian Conference on Dementia

Hot Topics 2026 | Oct 7, 2026 | Virtual



Conference Handbook

https://events.myconferencesuite.com/CCDHotTopics2026



Welcome to the Conference....4

How to use Zoom Events (Virtual Event Platform) 5

Detailed Program....6

Poster Presentations and Authors 10

Conference Evaluation, Certificate of Attendance, & Board 13

Conference Sponsors 14

Get the Most Out of CCD: Hot Topics 2026!

- Visit the **Poster Presentations** at **https://events.myconferencesuite.com/CCDHotTopics2026/page/Posters** to view the work being done by your colleagues, and hear the latest innovations in just 7 minutes during our **New and Notable Presentations** during Stream 2 of the morning concurrent sessions.
- Vote for your favourite Poster Abstract by 2:45 pm ET through the **People's Choice Awards for Best Poster**. The link to the online voting will be posted in the chat. Awards will be announced at the end of the day and Conference Services will follow up with the winners by email following the event.
    - First Place: $100 e-gift card & certificate
    - Second Place: $50 e-gift card & certificate
    - Third Place: $50 e-gift card & certificate
- Visit our **Sponsor booths in the Expo area** to interact with their representatives and learn more about them.
- Get your **Certificate of Attendance** and help us plan for next year. A link to the evaluation will be posted in the lobby chat and you will also receive an email from Conference Services with a link to our evaluation survey. Take a few minutes to fill in the evaluation and once you submit the evaluation, you will be able to access your certificate.
- For more information about CCD: Hot Topics 2026, visit **https://events.myconferencesuite.com/CCDHotTopics2026**



Welcome

Canadian Conference on Dementia: Hot Topics 2026

For over 20 years the Canadian Conference on Dementia (CCD) has been dedicated to advancing knowledge on dementia in scientific research and clinical care. This biennial in-person conference has become the preeminent academic national conference attracting more than 700 attendees in recent years. In 2024, we piloted a virtual meeting to be held on the alternate years to the in-person conference, to provide opportunity to hear from more international speakers, and keep up with rapid changes in the field regarding new medications, guidelines, diagnostic tools, and health services best practices. The virtual meeting was a success and so we are continuing with it.

The program this year will delve into topics such as: Subjective Cognitive Decline, Blood-Base Biomarker Use and Guidelines, Real-World Experience with DMTs, the Cellular Phase of AD, Cardiac Disease and Dementia Risk, Hearing and Dementia, Population Neuroscience and Dementia Syndemics, Mild Behavioural Impairment, Chatbots in Dementia Care, Sleep and Incident Dementia, Vascular Cognitive Impairment, and Future Directions in AD. We will also hear from the top abstract submissions in the New and Notable session addressing plasma biomarker use, sleep and menopause, and development of culturally responsive KTE products

Zahinoor Ismail, MD
Chair, Canadian Conference on Dementia

How to use Zoom Events (Virtual Event Platform)

Zoom Events is a platform designed to tie together multiple Zoom meetings into one website interface: webinars, meetings, breakout conference sessions, and sponsor exhibits.

Attendees can chat with individuals or groups in dedicated virtual spaces, and a single virtual booth can host multiple discussions.

Conference participants will join the event with one link. They will land in a virtual lobby and navigate to sessions from there.

The Lobby for the event shows the conference information at a glance with featured and upcoming sessions at the bottom, the Lobby Chat on the right, and the different conference areas/features on the top bar including:



- **Sessions**, where you'll be able to enter the presentations
- **Itinerary**, where you can build your personal agenda for the event
- **Expo**, where you'll find our sponsor booths with their downloadable resources, an area to chat with them, as well as a link to our Poster Presentations
- **Speakers**, where you'll find our speaker information

More information about Zoom Events as an Attendee can be found at

https://bit.ly/ZoomEventsInstructions_CCD2026.

If you run into any issues with the platform, please contact **conferences@uhn.ca**.

detailed program

TIME	SESSION
9:00 - 9:45	**Event platform opens to attendees to interact with sponsor exhibits. Posters are available for viewing on the conference website**
9:45 - 9:50	**Opening Remarks** **Zahinoor Ismail**, MD FRCPC – Conference Chair *Professor of Psychiatry, Neurology, Epidemiology, and Pathology, University of Calgary; Clinician Scientist, Hotchkiss Brain Institute and O'Brien Institute for Public Health*
PLENARY SESSION	
9:50 - 10:20	**Subjective Cognitive Decline and Stage 2 of Alzheimer's Disease** **Frank Jessen,** MD *Director of the Department of Psychiatry, University of Cologne; Group Leader for Clinical Alzheimer Research and Member of the Clinical Executive Board, German Center for Neurodegenerative Diseases (DZNE)* With the evolving causal treatment of AD, early disease detection gains in relevance. Stage 2 of AD refers to the initial symptomatic phase of the disease with subjective and subtle objective cognitive decline. The talk will summarize recent findings on stage 2 with specific focus disease course prediction.
10:20 - 10:30	**Transition to Concurrent Sessions**
CONCURRENT SESSIONS *The following three streams will run concurrently from 10:30 – 12:00. Each stream consists of three 30-minute presentations: 25 minutes presentation + 5 minutes Q & A.*	
STREAM 1: ALZHEIMER DISEASE ASSESSMENT AND MANAGEMENT	
10:30 – 11:00	**An Update on Blood Biomarkers for Neurodegenerative Disease and Factors Beyond CNS Pathophysiology that Affect their Interpretation** **Joel Simrén, MD, PhD** *Researcher, Department of Psychiatry and Neurochemistry, University of Gothenburg; Resident Physician in Clinical Chemistry, Sahlgrenska University Hospital* In this lecture, Dr. Simrén will review the latest advances in blood biomarkers for neurodegenerative diseases, with a focus on biomarkers for AD pathology. He will also discuss factors beyond CSN pathophysiology that are important to be aware of when ordering and interpreting this new class of biochemical tests
11:00 – 11:30	**Blood-based Biomarkers in the Clinical Diagnosis of Alzheimer's Disease** **Suzanne Schindler, MD, PhD** *Professor of Neurology, Washington University School of Medicine; Leader of the Fluid Biomarker Core, Knight Alzheimer Disease Research Center* This talk will describe the use of blood-based biomarkers in clinical diagnosis of symptomatic Alzheimer's disease. It will include discussion of which blood tests are most accurate, current limitations of blood tests, when a second test should be performed, and how to integrate clinical information and blood test results.
11:30 – 12:00	**DMT Real-World Experience** **Vijay K. Ramanan, MD, PhD** *Associate Professor of Neurology and Director of the Alzheimer's Disease Treatment Clinic, Mayo Clinic; Consultant in the Division of Cognitive/Behavioral Neurology, Department of Neurology, Mayo Clinic* Attendees will learn insights from the early experience of implementing anti-amyloid therapies to real-world clinical practice, including structures for baseline eligibility assessments and longitudinal treatment monitoring as well as areas of active debate and investigation in the field for current and future therapeutic optimization.

Video recordings of the presentations that we receive consent to share will be made available to registered attendees post event. An email notification with instructions will be provided within a few weeks following the conference.



TIME	SESSION
STREAM 2: RESEARCH SPOTLIGHT - SCIENTIFIC HIGHLIGHTS IN DEMENTIA RESEARCH	
10:30 – 11:00	**New and Notable** *(7 minutes presentation + 3 minutes Q & A)* **Top 3 Abstracts** ***The top 3 abstracts taken from the Call for Abstracts will have 7 minutes each to present with 9 minutes after all oral abstract for a group Q & A.*** **Real-World Clinical Experience with more than Thousand ALZpath Plasma p-tau217 Testing in a Canadian Diagnostic Laboratory** **Hans Frykman,** MD, PhD, FRCPC **Associations Between Later-Life Sleep Disturbance Burden and Later-Life Cognitive and Behavioural Changes in Postmenopausal Females** **Sanvi Langay**, Undergraduate Student **Co-Designing Culturally Responsive KTE Products with Ethnocultural Communities to Bridge Community Needs and Health Policy** **Zaina Alsibai**, MSC
11:00 - 11:30	**Clinical, and Subclinical Cardiac Disease and Risk of Dementia** **Michelle Johansen, MD, PhD, FAHA, FANA** *Associate Professor of Neurology at the Johns Hopkins University School of Medicine* This presentation will examine the expanding body of evidence linking clinical and subclinical cardiac disease—including atrial fibrillation, atrial cardiopathy, and echocardiographic and biomarker-based measures of cardiac dysfunction—to cognitive decline and dementia risk. Drawing on population-based cohort data and mechanistic studies, the talk will address how cardiac pathology may contribute to cognitive impairment through pathways that extend beyond overt clinical stroke, including covert cerebral injury, chronic cerebral hypoperfusion, and systemic inflammatory processes. The session will conclude with a discussion of key knowledge gaps and opportunities for interdisciplinary collaboration across cardiology, neurology, and dementia research to advance prevention strategies.
11:30 - 12:00	**The Cellular Phase of Alzheimer's Disease** **Bart De Strooper, MD, PhD** *Professor (Molecular Medicine), KU Leuven and VIB; Group Leader, UK Dementia Research Institute (UK DRI), University College London and Francis Crick Institute* Alzheimer's disease is widely depicted as a linear cascade from amyloid-β accumulation to Tau pathology and neurodegeneration. We propose instead that the disease unfolds through discrete molecular, cellular and network phases organized around biological inflection points. At these thresholds, stress-driven loss of homeostasis produces qualitative shifts in cellular behavior that alters disease progression. These altered states spread across local tissue-domains, accumulate as a mosaic across the brain, and progressively engage vulnerable centres of information processing that control cognitive performance. The induction of amyloid-associated Tau phosphorylation marks a pivotal inflection point, separating amyloid-dominated tissue states from domains in which neuronal Tau stress responses have emerged. This framework helps reconcile the dissociation between pathology and symptoms, clarifies the shared architecture of familial and sporadic disease and reframes Alzheimer's disease as a disorder shaped by biological thresholds, timing, and progressive erosion of homeostatic resilience.
STREAM 3: PUBLIC HEALTH & EPIDEMIOLOGY	
10:30 - 11:00	**Hearing and Dementia: From Ears to Brain** **Jason Warren, PhD FRACP** *Professor of Neurology, University College London; Consultant Neurologist, National Hospital for Neurology and Neurosurgery* Impaired hearing is associated with cognitive decline in dementia, but the basis for this association is not clear. I will present evidence that the auditory brain is targeted early in major neurodegenerative diseases, notably Alzheimer's disease and frontotemporal dementia, leading to disorders of auditory cognition or 'brain hearing'. Auditory cognitive deficits constitute novel candidate markers of neural dysfunction in these dementias and impact hearing and communication in the noisy listening environments of daily life.
11:00 - 11:30	**Population Neuroscience and Dementia Syndemics: Using Systems to Address a Global Health Crisis** **Ganesh Babulal, PhD OTD MSCI MOT OTR/L** *Professor, Mayo Clinic - Rochester* This talk introduces the Population Neuroscience–Dementia Syndemics Framework, which examines how social, political, economic, environmental, and biological factors interact across the life course to shape dementia risk. Attendees will learn how this approach can identify sex- and gender-based inequities, particularly in low- and middle-income countries and guide more representative research, effective prevention strategies, and equitable global health policy.

TIME	SESSION
11:30 - 12:00	**Why We Should Care about Mild Behavioural Impairment (MBI)** **Constantine (Kostas) G Lyketsos, MD, MHS** *Elizabeth Plank Althouse Professor and Chair, Johns Hopkins University; Clinical Core Leader, Johns Hopkins Alzheimer's Disease Research Center (ADRC); Founder, Richman Family Precision Medicine Center of Excellence on Alzheimer's Disease* This presentation will provide an overview of the current understanding and management of neuropsychiatric symptoms (NPS) in Alzheimer's disease, highlighting their impact throughout the disease continuum. Participants will explore the concept of neuropsychiatric symptoms emerging before the onset of dementia and the development of the Mild Behavioral Impairment (MBI) construct as a framework for identifying and understanding these early changes. The session will also examine current challenges, emerging research directions, and future opportunities for the study and treatment of MBI, with the goal of improving early detection and intervention strategies in Alzheimer's disease.
12:00 - 13:30	**Lunch, networking with sponsors, poster viewing**
CONCURRENT PARALLEL SESSIONS *Two sessions will run concurrently from 13:30 – 14:30. Each stream consists of two 30-minute presentations*	
PARALLEL 1: ACROSS THE COGNITIVE CONTINUUM	
13:30 – 14:00	**How Can AI Chatbots Support Dementia Care?** **Ipsit Vahia, MD** *Associate Professor of Psychiatry, Harvard Medical School; Chief, Division of Geriatric Psychiatry, McLean Hospital* At the end of this talk, attendees will be able to (a) categorize common caregiver questions into algorithmic format (b) recognize how humans enabled with AI tools may be more effective at dementia care (c) understand how AI chatbots can create new efficiencies in care.
14:00 – 14:30	**Sleep and Incident Dementia** **Kristine Yaffe, MD** *Distinguished Professor of Psychiatry, Neurology, and Epidemiology, University of California, San Francisco; Director of the Center for Population Brain Health, University of California, San Francisco* Sleep changes and disturbances are common in older adults. Critically, increasing evidence links sleep quality and sleep disorders to risk of cognitive impairment and dementia, and the field is now beginning to explore the potential for prevention.
PARALLEL 2: BIOMARKER GUIDELINES AND RECOMMENDATIONS	
13:30 – 14:00	**Alzheimer's Association's Guidelines for Blood-based Biomarkers: Where We Are Now and What's Around the Corner** **Heather Whitson, MD MHS** *Professor of Medicine, Duke University School of Medicine; Co-Director, Duke/UNC Alzheimer's Disease Research Center* This presentation will provide an overview of the Alzheimer's Association's Clinical Practice Guidelines (CPG) for the use of blood-based biomarkers in the diagnosis of Alzheimer's disease. Participants will learn about the key clinical questions addressed to date, current recommendations, and the evolving role of blood-based biomarkers in clinical practice. The session will highlight updates anticipated in the next iteration of the guidelines, including considerations related to commercially available tests and the use of two cut-off approaches to support ruling in or ruling out brain amyloid pathology. In addition, attendees will gain an understanding of pre-test probability and how it influences the interpretation of biomarker results, including positive and negative findings, to support accurate and informed clinical decision-making.
14:00 – 14:30	**Canadian Plasma Biomarker Appropriate Use Recommendations** **Zahinoor Ismail, MD FRCPC** *Professor of Psychiatry, Neurology, Epidemiology, and Pathology, University of Calgary; Clinician Scientist, Hotchkiss Brain Institute and O'Brien Institute for Public Health* This presentation will provide an overview of the upcoming Canadian Plasma Biomarker Appropriate Use Recommendations, which is a practical and concept-based document intended to help clinicians navigate this rapidly evolving field. We will review biomarker nomenclature and definitions, explore the different platforms and assays, discuss specific use cases, and provide general guidance on how to apply basic principles across different settings.



TIME	SESSION
14:30 - 14:45	**Break**
PLENARY SESSIONS	
14:45 - 15:15	**Future Directions in Alzheimer's Disease/ADRD Research** **Heather Snyder, PhD** *Senior Vice President, Medical and Scientific Operations, Alzheimer's Association* This presentation will focus on the future directions of research across the entire spectrum of the cognitive continuum. As new studies report out, there is a clear link to cognitive resilience and behavioral change; what are some of the big questions in this research space and what are the studies actively ongoing aimed to address these? This will highlight exciting new research directions focused on brain health and risk reduction. At the same time, the space of therapeutic and diagnostic development continues to expand. New tools and potential avenues for considering diagnostics that span co-pathologies are evolving and gaining a better and deeper understanding. A discussion about this evolving area of research and what this may mean for diagnosis and clinical care will be included. This also ties to therapeutic development, and new avenues for the clinical pipeline in the AD/ADRD space, including combination approaches and how technology is being applied to accelerate therapeutic development.
15:15 - 15:45	**The VasCog-2-WSO Criteria for Vascular Cognitive Impairment and Dementia (VCID)** **Perminder Sachdev, MD PhD FRANZCP** *Scientia Professor of Neuropsychiatry, UNSW Sydney; Co-Director, Centre for Healthy Brain Ageing (CHeBA); Clinical Director, Neuropsychiatric Institute, Prince of Wales Hospital* This talk will provide an overview of the VasCog-2-WSO criteria for diagnosing vascular cognitive disorders, highlighting key updates in clinical, cognitive, and neuroimaging assessment. It will discuss how the criteria can support more consistent diagnosis, improve research comparability, and guide clinical decision-making in patients with cognitive impairment related to cerebrovascular disease.
15:45 - 16:00	**Closing Remarks** **Zahinoor Ismail**, MD FRCPC – Conference Chair *Professor of Psychiatry, Neurology, Epidemiology, and Pathology, University of Calgary; Clinician Scientist, Hotchkiss Brain Institute and O'Brien Institute for Public Health*
16:00 - 17:00	**Poster Viewing** Posters are available for viewing on the conference website at **https://events.myconferencesuite.com/CCDHotTopics2026/page/Posters**

Video recordings of the presentations that we receive consent to share will be made available to registered attendees post event. An email notification with instructions will be provided within a few weeks following the conference.

poster presentations and authors

#	Poster Title and Authors	Representative(s)
1	VR&R Trial: Interim Results on the Use of Virtual Reality to Support Caregiver Respite in Dementia Care *Vanessa Geitz, Samantha Lewis-Fung, Sahil Patel, Mattaya Pallett, Essete Tesfaye, Lora Appel*	Vanessa Geitz
2	Lived Experience is More than a Checkbox: Meaningful Inclusion of Lived Experience perspective in Seniors Mental Health System Planning *Kim Schryburt-Brown, Kathy Baker, Sharon Osvald*	Kim Schryburt-Brown, Sharon Osvald, & Kathy Baker
3	Co-designing culturally responsive KTE Products with ethnocultural communities to bridge community needs and health policy *Zaina Alsibai, Sathya Karunananthan, Sanjna Navani, The Alzheimer's Indonesia Toronto, African Canadian Development and Prevention Network, Alexie Dechênes, Rachel Samson, Marie Christine Le Bourdais, Mirielle Norris, Howard Bergman, Isabelle Vedel, Claire Godard-Sebillotte*	Zaina Alsibai
4	Primary Care Provider-to-Specialist Communication Services Across Canada for Persons with Dementia: An Environmental Scan *Shruthi Sundararaman, Sarah Syed, Kunal Dalsania, Jean-Denis Lalonde, Nalia Gurgel-Juarez, Amanda Wilson, Celeste Fung, Frank Knoefel, Julia Chabot, Claire Godard-Sebillotte, Clare Liddy, Isabella Moroz, Laura Visentin, Suey Shuk Yu Yeung, Sathya Karunananthan*	Sarah Syed
5	Paid caregivers of research participants with dementia: the unexplored ethical risks of transposed incentives, involuntary intermediaries, and pre-existing power structures *Jill Oliver, Paola Cubillos*	Jill Oliver
6	What Should Dementia Care Look Like Moving Forward? Perspectives of caregivers, faculty, and healthcare professionals *Winnie Sun*	Winnie Sun
7	Centralized clinical navigation and referral management to transform Behavioural Supports through standardized data and indicator capture *Sophia Kim, Varsha Jayaraman, Laura Harrison, Leslie Shafran, Lauren Masci*	Sophia Kim, & Laura Harrison
8	Normative data for the MoCA - Language (MoCA-L): A new screening tool for language disorders in neurodegenerative diseases *Robert Jr Laforce, Monica Lavoie, Guillaume Duboisdindien, Joël Macoir, Ziad Nasreddine*	Robert Laforce
9	Bridging the Gap: Designing a Transferable Disease-Modifying Therapy Pathway for Alzheimer's Dementia *Rebecca Lee, Alex Tamm, Daisy Fung, Lesley Charles, Oksana Suchowersky, Kareena Schnabl, Richard Camicioli, Valerie Sim*	Rebecca Lee
10	Individuals living with Dementia and requesting Medical Assistance in Dying (MAiD): A retrospective descriptive study *Sara Olivier, Genevieve Casey, Jennifer Batista*	Genevieve Casey
11	Mild behavioural impairment and falls among dementia-free older Canadians: a cross-sectional study *Ibadat Warring, Dylan Guan, Maryam Ghahremani, Zahinoor Ismail*	Ibadat Warring
12	Vascular Risk as a Predictor of Treatment Response in the EXACT Trial *Maya Mills, Julian Schecter, Damien Gallagher, Melissa Wong, Ana Andreazza, Sandra Black, Xingshan Cao, Jocelyn Charles, Fuqiang Gao, Nathan Hermann, Bradley MacIntosh, Giovanni Marotta, Susan Marzolini, Sara Mitchell, Paul Oh, Tarek Rajji, Mark Rapoport, Mehreen Siddiqui, Krista Lanctôt*	Maya Mills
13	A Theory-Guided Dual-task Intervention for Community-Dwelling Older Adults with Mild Cognitive Impairment: Study Protocol *Lu Chen, Yue Zhao, Qingqing Dai, Fengli Gao*	Qingqing Dai
14	Augmented Exercise Interventions: Optimizing Response to Exercise Modalities for Cognitive Enhancement in Early AD *Julian Schecter, Yejin Kang, Sandra Black, Nathan Herrmann, Sara Mitchell, Susan Marzolini, Paul Oh, Jennifer Rabin, Tarek Rajji, Mark Rapoport, Walter Swardfager, Mehreen Siddiqui, Kate Survilla, Damien Gallagher, Krista Lanctôt*	Julian Schecter
15	Evidence for mild behavioural impairment in biomarker-defined Alzheimer's disease clinical staging: An ADNI study *Dylan Guan, Maryam Ghahremani, Daniella Vellone, Eric Smith, Zahinoor Ismail*	Dylan Guan



#	Poster Title and Authors	Representative(s)
16	Validation of Neuropsychiatric-Inventory Clinician apathy domain items for apathy screening in patients with neurocognitive disorders *Krushnaa Sankhe, Valeria Manera, Julia Castel, Rajbir Singh, Dov Gandell, Giovanni Marotta, Damien Gallagher, Mark Rapoport, David S. Miller, Kritleen K. Bawa, Jeffrey L. Cummings, Larry Ereshefsky, Masud Husain, Zahinoor Ismail, Jacobo Mintzer, Hans J. Moebius, Moyra E. Mortby, Anton P. Porsteinsson, Philippe Robert, Carla Zucchero Sarracini, Danielle Vieira, Krista L. Lanctôt*	Krushnaa Sankhe
17	Assessing the correlation between FDG-PET CT scan imaging in Long COVID patients with subjective cognitive symptoms, and objective cognitive testing *Angela G Juby, Christopher MJ Davis, Ryan Hung, Jonathan Abele*	Angela Juby & Christopher Davis
18	Comparing subjective cognitive complaints with cognitive scores and dual-task walking in a group of long COVID participants *Christopher MJ Davis, Angela G Juby*	Angela Juby & Christopher Davis
19	Clinical Evaluation of the Elecsys® Phospho-Tau (217P) Plasma IVD Assay: Establishing Dual Cutoffs for Primary and Secondary Care *Annunziata Di Domenico, Sayuri Hortsch, David Caley, Niels Borlinghaus, Kaj Blennow, Oskar Hansson, Marc Suárez-Calvet, Craig W. Ritchie, Nicholas J. Ashton, Marisa Denkinger, Christopher C. Rowe, Ming Lu, Sameera R. Wijayawardana, Alonso Montoya, Sebastian Palmqvist*	Alonso Montoya
20	Cross-sectional associations of perimenopausal symptoms with clinical markers of dementia risk *Jasper Crockford, Dylan Guan, Maryam Ghahremani, Zahinoor Ismail*	Jasper Crockford
21	Improving and Sustaining Comfort Cart Use in Emergency Departments to Support Delirium Prevention and Management Among Older Adults: A Quality Improvement Initiative *Sylvia Quant, Camille Bugo, Andrea Hong, Linda Liu, Inderjeet Singh, Kristen Lee, Victoria Dishman, Lauren Lapointe-Shaw, Tessa Ringer, Nazek Abdelmutti*	Sylvia Quant, & Camille Therese Bugo
22	Implementing Anti-Amyloid Therapy into a Regional Memory Clinic: A Systems-Based Rollout *Liz Legace, Lianne Cloutier, Andrea Jewell, Katie Churchill, Veronique French, Neil Thomas, Andrew Frank*	Lianne Cloutier
23	Investigating grey matter volume and cerebral blood flow as biomarkers of cognitive resilience in a population at risk for vascular cognitive impairment and dementia *Melissa Wong, Guocheng Jiang, Damien Gallagher, Bradley J. MacIntosh, Sandra E. Black, Fuqiang Gao, Joel Ramirez, Nathan Herrmann, Mark J. Rapoport, Yejin Kang, Kate Survilla, Danielle Vieira, Krista L. Lanctôt*	Melissa Wong
24	Associations between later-life sleep disturbance burden and later-life cognitive and behavioural changes in postmenopausal females *Sanvi Langay, Ibadat Warring, Maryam Ghahremani, Dylan Guan, Gurshaan Sidhu, Zahinoor Ismail*	Sanvi Langay
25	Subjective cognitive decline and Alzheimer's disease-related plasma biomarkers across ethnoracial groups: findings from the CAMERA study *Simran Malhotra, Georgia Gopinath, Madeline Alexander Wood, Rohina Kumar, Valery Sit, Angelina Zhang, Ravetta Ravichandran, Krisha Khanna, Ella Kim, Mikayla Lisi, Tulip Marawi, Katie Vandeloo, Rachel Yep, Walter Swardfager, Sandra Black, Maged Goubran, Jennifer Rabin*	Simran Malhotra
26	Childhood Household Environment and Later-Life Plasma p-Tau Across Canadian Ethnoracial Groups *Rohina Kumar, Madeline Wood Alexander, Krisha Khanna, Simran Malhotra, Valery Sit, Angelina Zhang, Ravetta Ravichandran, Ella Kim, Mikayla Lisi, Tulip Marawi, Katie L. Vandeloo, Rachel Yep, Walter Swardfager, Maged Goubran, Sandra Elizabeth Black, Jennifer S. Rabin*	Rohina Kumar
27	Relationship between menopausal symptoms and task-induced cortical hemodynamic response in midlife: an fNIRS Study *Wejdaan Faridi, Burma Joel, Cindy Barha*	Wejdaan Faridi
28	A scalable fMRI marker of hippocampal excitation-inhibition balance that tracks MEG electrophysiology in aging *Kevin Solar, Luis Garcia Dominguez, Richard Wennberg, Ljubica Zotovic, Krista Lanctôt, Sandra Black, Sanjeev Kumar, Mary Pat McAndrews*	Kevin Solar
29	Factorial Validation of the Mild Behavioral Impairment Checklist in Clinic and Community-Dwelling Samples *Ibadat Warring, Maryam Ghahremani, Tolulope Sajobi, Eric E. Smith, Zahinoor Ismail*	Ibadat Warring

poster presentations and authors

#	Poster Title and Authors	Representative(s)
30	Real-World Distributions of ALZpath and Lumipulse Plasma p-tau217 Test Results: Experience from More Than 1,600 Tests at a Canadian Diagnostic Laboratory *Pankaj Kumar, Ali Mousavi, Mary Encarnacion, YiLiang (Betty) Zhang, Ryan Conkling, Hans Frykman*	Pankaj Kumar
31	Real-World Clinical Experience with more than Thousand ALZpath Plasma p-tau217 Testing in a Canadian Diagnostic Laboratory *Ali Mousavi, Pankaj Kumar, Mary Encarnacion, YiLiang (Betty) Zhang, Ryan Conkling, Hans Frykman*	Hans Frykman
32	A Scoping Review on the Diagnosis and Management of Vascular Parkinsonism *Jean Triscott, Peter Tian, Eric Lui, Janice Kung, Lesley Charles*	Jean Triscott
33	Clinical Experience with Lumipulse Plasma p-tau217 Testing in a Canadian Diagnostic Laboratory *Pankaj Kumar, Ali Mousavi, Mary Encarnacion, YiLiang (Betty) Zhang, Ryan Conkling, Hans Frykman*	Pankaj Kumar
34	A Seed Amplification Assay Detecting Pathological Alpha-Synuclein in Parkinson's Disease and Dementia with Lewy Bodies *Cyril Helbling, Mari L. DeMarco*	Cyril Helbling
35	Agitation Composite Score as a Predictor for Clinical Severity and Functional Disability Across Frontotemporal Lobar Degeneration *Celine N. Sakran, M. Carmela Tartaglia*	Celine Sakran
36	Disease-Modifying Therapies in Dementia: Assessment of Knowledge, Educational Needs, and Practice Readiness for Implementation in Geriatricians in Canada *Lesley Charles, Diana Rucker, Rebecca Lee, Janelle Wai, Ariana Filiplic, Jean Triscott, Peter Tian*	Lesley Charles
37	Accessing and Navigating Dementia Care Among First-Generation Chinese Immigrant Older Adults and Their Caregivers in Quebec: An Interpretive Description Study *Claire Godard-Sebillotte, Isabelle Vedel, Winda Hao*	Winda Hao
38	Building a Provincial Memory Café Network in Nova Scotia: Participant Well-being and Social Connection Outcomes for Persons Living with Dementia *Bryah Boutilier, Beverley Cassidy*	Bryah Boutilier
39	Is the same workplace behaviour viewed differently in the presence of a dementia diagnosis? A randomized vignette study *Judith Godin, Jasmine Mah, Nicolas Roulin, Katie Aubrecht, Melissa K. Andrew*	Judith Godin
40	Structural Exclusion by Design: The Absence of Indigenous-Led Knowledge Translation in Central Toronto's Dementia Day Programs *Hom Shrestha, Hung Nguyen, Lucy Shrestha, Art Petahtegoose*	Hom Shrestha
41	Educating the Next Generation for Dementia Prevention: Do Future Rehabilitation and Fitness Professionals Understand What Motivates Older Adults to Exercise? *Patricia Hewston, Caroline Marr, Matthew Bosnich, Alexandra Jackson, Christine Wilkinson, Rachel Brown, Alexandra Papaioannou*	Patricia Hewston
42	Reframing dementia care beyond prescription: a 10-year global roadmap for brain health, prevention, and health-system transformation *Jeya Thayaparan, Ganeshmoorthy Arunachalam, Pamela Baxter, Thavarajah Nirusha, Umaharan Thamotharampillai, Katarina Lakovic, Asvini Thayaparan, Angelina Yogarajah, Cinzia Amutharaja, Belinda Robinson, Alejandra Villalobos*	Jeya Thayaparan & Ganesh Arunachalam
43	Housing as a Prescription for Brain Health: Reimagining Dementia Care Beyond the Clinic—International Models Informing a Canadian Policy Framework *Jeya Thayaparan, Auvei JeyaKumar, Angelina Yogarajah, Kavitha Jayaram, Pamela Baxter*	Jeya Thayaparan & Jhon Mark Cana
44	Cognitive reserve as a moderator of the association between plasma phosphorylated tau-217 and gait, hearing, and vision in older adults: work-in-progress *Gurshaan Sidhu, Dylan Guan, Maryam Ghahremani, Zahinoor Ismail*	Gurshaan Sidhu

#	Poster Title and Authors	Representative(s)
45	Early-Life Adversity and the Protective Effect of Cortical Thickness on Dementia Risk in Older Adults *Dinithi Mudalige, Dylan Guan, Peter Chan, Zahinoor Ismail*	Dinithi Mudalige
46	Beyond Prescriptions, Beyond Geriatrics: Developing a Certificate of Competency in Dementia Care to Strengthen Canada's Healthcare Workforce *Jeya Thayaparan, Katarina Lakovic, Cinzia Amutharaja, Belinda Robinson, Pamela Baxter, Nirusha Thavarajah*	Jeya Thayaparan & Angelina Yogarajah
47	From childhood adversity to dementia risk: investigating the associations between adverse childhood experiences, anxious distress, and later life functional impairment in dementia-free community-dwelling older adults *Sasha Holub, Ibadat Warring, Gurshaan Sidhu, Maryam Ghahremani, Dylan Guan, Sanvi Langay, Zahinoor Ismail*	Sasha Holub
48	A Comprehensive Inventory of Databases Supporting Intersectional Health Equity Research for Persons with Dementia in Canada *Magnolia Miller, Dimitri Yang, Stefanie Tremblay, Sathya Karunananthan, Claire Godard-Sebillotte*	Magnolia Miller
49	The impact of cognitive impairment on eye gaze during everyday task completion by older adults *Christina Commisso, Shital Desai, Rosalie Wang, Andrea Iaboni, Alex Mihailidis, Arlene Astell*	Christina Commisso
50	DEEPENSE-CogAI: an explainable AI-enabled cognitive risk and care-navigation model for older adults, with an equity focus on underserved and Indigenous communities *Jeyasakthy Thayaparan, Eilya Parsa, Kawsitha Sivakumaran, Pamela Baxter*	Jeya Thayaparan & Samarrann Sivaloganathan

Conference Evaluation and Certificate of Attendance

Delegate feedback is very important to the committee as it helps to guide the planning process for future conferences.

Please note that when you open up the online evaluation, you must complete the entire survey. If you close out of the survey, it will not save.

The evaluation can be easily accessed on your smart phone/ tablet / laptop via the link below.

Evaluation Link: **https://www.surveymonkey.com/r/2026CCDEval**

After you complete the survey in its entirety, and click DONE, you will be directed to your Certificate of Attendance.

Board and Organizing Committee

Zahinoor Ismail - Chair *Hotchkiss Brain Institute; University of Calgary*

Sandra E. Black *Sunnybrook Health Science Centre, University of Toronto*

Howard Chertkow *Canadian Consortium on Neurodegeneration in Aging; Baycrest; McGill University; University of Toronto*

Serge Gauthier *McGill University*

Zahra Goodarzi *Hotchkiss Brain Institute; University of Calgary*

Dylan Guan *University of Calgary*

Ging-Yuek Robin Hsiung *University of British Columbia; Consortium of Canadian Centres for Clinical Cognitive Research; Canadian Consortium on Neurodegeneration and Aging*

Mary Pat McAndrew *Krembil Brain Institute, University Health Network; University of Toronto*

Gary Naglie *University of Toronto; Baycrest Health Sciences*

Jacqueline Pettersen *University of British Columbia*

Saskia Sivananthan *Brainwell Institute; McGill University*

Eric Edward Smith *University of Calgary*

LEQEMBI®
Lecanemab for Injection
SOLUTION FOR INFUSION

LEQEMBI® (lecanemab for injection) is indicated for the treatment of adult patients with a clinical diagnosis of MCI or mild dementia due to AD (early AD), who are ApoE ε4 noncarriers or heterozygotes, and who have confirmed amyloid pathology.[1]

LEQEMBI® has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization.

The first anti-amyloid-ß mAB indicated in early Alzheimer's disease*,[1,2]



INTRODUCING LEQEMBI®

A new treatment for early Alzheimer's patients

STAY INFORMED ABOUT LEQEMBI®

Consult the Product Monograph at leqembicanada.ca/PM-ENG for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling Eisai Medical Information at 1-877-873-4724.

mAB: monoclonal antibody; MCI: mild cognitive impairment; AD: Alzheimer's disease; ApoE ε4: apolipoprotein E ε4
*Comparative clinical significance is unknown.

References: 1. LEQEMBI® Product Monograph. Eisai Limited. October 24, 2025. **2.** Data on file. Eisai Limited.

Eisai Biogen

LEQEMBI® is a registered trademark of Eisai R&D Management Co., Ltd.
© 2026 Eisai Inc. and Biogen. All trademarks and company names are the property of their respective owners.
LECA-CA2131E Biogen-287466E

REVIEWED BY PAAB



Lilly

A MEDICINE COMPANY

UNE COMPAGNIE DE MÉDECINE



©2026 Eli Lilly Canada Inc. All rights reserved.

PP-ALZ-CA-0023

Excellence in Neurodiagnostics

go.roche.com/diagnostics.neurology



Thank you to our Sponsors

Platinum Sponsors

Gold Sponsor

conferences@uhn.ca

canadianconferenceondementia.org